Article Contents ::
- 1 The Brand Name PROPAL Has Generic Salt :: Propranolol
- 2 PROPAL Is From Company Svizera Priced :: Rs. 15.35
- 3 PROPAL have Propranolol is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name PROPAL Has Generic Salt :: Propranolol
PROPAL Is From Company Svizera Priced :: Rs. 15.35
PROPAL have Propranolol is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Tuberculosis, Hypertrophic cardiomyopathy, MI, Anxiety, Diabetic nephropathy, HTN, Cardiac arrhythmias, Angina pectoris, Phaeochromocytoma, Migraine prophylaxis, Essential tremor
Drug Dose ::
Adults Hypertension: As starting dose of 80mg twice a day may increased at weekly intervals according to response. The usual dose range is 160-320mg per day. With concurrentdiuretic or other antihypertensive drugs a further reduction of blood pressure is obtained. Angina, anxiety,migraine and essential tremor: A staring dose of 40mg two or three times daily may be increased by the same amount at weekly intervals according to patients’ response. An adequate response in anxiety, migraine and essential tremor is usually seen in the range 80-160mg/day and an angina in the range 120-240mg/day. Situational and generalized anxiety: A dose of 40mg daily may provide short term relief of acute situational anxiety. Generalized anxiety require long term therapy, usually responds adequately to 40mg twice daily which, which individual cases, may be increased to 40mg three times daily. Treatment should be continued according to responses. Patients shouldreviewed after 6 to12 months treatment. Dysarhythmias, anxiety tachycardia, hypertrophic obstructive cardiomyopathy and thyrotoxicosis: A dosage range of 10-40mg three or four times a day usually achieves the required response. Post myocardial infarction:Treatment should be started between days 5 and after 21 after myocardial infarction,with an initial dose of 40mg four times a day for 2 or 3 days. In order to improve compliance the total daily doses three after be given as 80mg twice a day. Phaeochromocytoma (Used only with an alpha receptor blocking drug). Pre-operative: 60mg daily for three days. Non-operable malignant cases: 30mg daily. Children: Sysrhythmias, Phaeochromocytoma,Thyrotoxicisis: Dosage should be individually determined and the following is only a guide.0.25-0.5mg/kg three or four times daily as required. Migraine Under 12 years: 20mg two or three times daily. Over 12 years: The adult dose. As Extended release Capsule: Hypertension Dosage Must Be Individualized. The usual initial dosage is 80 mg propranolol hydrochloride extended-release capsules once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks. Angina Pectoris Dosage Must Be Individualized. Starting with 80 mg propranolol hydrochloride extended-release capsules once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established. If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks. Migraine Dosage Must Be Individualized. The initial oral dose is 80 mg propranolol hydrochloride extended-release capsules once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, propranolol hydrochloride extended-release capsules therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks. Hypertrophic Subaortic Stenosis 80 mg to 160 mg propranolol hydrochloride extended-release capsules once daily.
Propranolol hydrochloride is contraindicated in 1) cardiogenic shock; 2) sinus bradycardia and greater than first-degree block; 3) bronchial asthma; 4) congestive heart failure (see WARNINGS), unless the failure is secondary to a tachyarrhythmia treatable with propranolol hydrochloride.
Drug Precautions ::
Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol is not indicated for the treatment of hypertensive emergencies. Beta-adrenoreceptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure. Risk of Anaphylactic Reaction While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
Drug Side Effects ::
Most adverse effects have been mild and transient and have rarely required the withdrawal of therapy. Cardiovascular: Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type. Central Nervous System: Lightheadedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; reversible mental depression progressing to catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate formulations, fatigue, lethargy, and vivid dreams appear dose related. Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, and ischemic colitis. Allergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, pharyngitis and agranulocytosis, erythematous rash, fever combined with aching and sore throat, laryngospasm, and respiratory distress. Respiratory: Bronchospasm. Hematologic: Agranulocytosis, nonthrombocytopenic purpura, and thrombocytopenic purpura. Skin: Stevens-Johnson Syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and urticaria.
Pregnancy category ::
Drug Mode of Action ::
Propranolol is a non-cardioselective ?-blocker that competitively blocks ?1- and ?2-receptors resulting in decreased heart rate, myocardial contractility, BP and myocardial oxygen demand. It has membrane-stabilising properties.
Drug Interactions ::
Antidiabetics, verapamil, diltiazem, lignocaine, ergotamine, dihydroergotamine, indomethacin, chlorpromazine, anaesth, disopyramide, quinidine, amiodarone, digitalis glycosides, cimetidine, hydralazine, adrenaline, alcohol.